AbbVie

News
lillyhq

Lilly aims for new indication for Taltz

Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.

News
AbbVie's Humira (adalimumab)

Novartis files Humira biosimilar in US

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires.